Annual report conducted by on behalf of the European Commission on the impacts of the increased biosimilar competition in Europe.
This study financed by the Third Health Programme examined the feasibility and impact of certain refinements of the mortality indicator.
Available in 8 EU languages
Available in 23 EU languages
Basic information targeted at medical device manufacturers, including FAQs.
Available in all EU languages and Arabic, Chinese, Japanese, Russian